DBV Technologies (NASDAQ:DBVT) Stock Passes Above 50-Day Moving Average - What's Next?

Key Points

• DBV Technologies' shares have recently surpassed their 50-day moving average, trading at $9.82 after reaching a high of $10.38.
• Analysts have mixed views on the stock, with targets ranging from $7.25 by Goldman Sachs to $21.00 by JMP Securities, reflecting a consensus rating of "Moderate Buy".
• The company reported significant earnings miss at ($1.55) EPS, despite a revenue of $1.74 million that exceeded expectations for the quarter.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $9.57 and traded as high as $10.38. DBV Technologies shares last traded at $9.82, with a volume of 98,148 shares.

Analyst Ratings Changes

DBVT has been the subject of several research analyst reports. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. The Goldman Sachs Group upgraded DBV Technologies to a "sell" rating and set a $7.25 target price for the company in a research note on Thursday, May 29th. Lifesci Capital upgraded DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. Finally, JMP Securities reiterated a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research note on Thursday, June 26th. Two investment analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $14.75.

DBV Technologies Stock Performance

The firm has a market capitalization of $268.70 million, a price-to-earnings ratio of -2.06 and a beta of -0.58. The company has a fifty day moving average of $9.61 and a two-hundred day moving average of $7.66.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%. Equities analysts forecast that DBV Technologies S.A. will post -7.05 EPS for the current year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.